Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. NAVN
10. DFTX

Go back to Madrigal Pharma (MDGL) Confirms FDA Approval of Rezdiffra for Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosi

March 14, 2024 4:15 PM EDT

Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as MASH)
Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved liver fibrosis and resolved NASH in patients with noncirrhotic NASH with moderate to advanced liver fibrosis Rezdiffra prescribing information does not include a liver biopsy requirement for diagnosisMadrigal conference call scheduled for March 14, 2024, at 5:15 pm ET

CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical... More